Company news

Arbutus Biopharma Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

October 10, 2023

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

September 10, 2023

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

August 2, 2023

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

July 19, 2023

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

July 11, 2023

Arbutus Appoints Two New Executives

July 9, 2023

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

June 20, 2023

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

June 20, 2023

Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023

June 6, 2023

Arbutus to Present at Jefferies Healthcare Conference

May 30, 2023

Arbutus to Present at JMP Securities Life Sciences Conference

May 8, 2023

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update

May 3, 2023

Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023

April 26, 2023

Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor

April 24, 2023

Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update

April 19, 2023

Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023

April 17, 2023

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech

April 3, 2023

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

March 15, 2023

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

March 13, 2023

Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update

March 1, 2023

Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update

February 15, 2023

Arbutus to Participate in Three Upcoming Investor Conferences

February 5, 2023

Arbutus Announces Resignation of Board Member

January 26, 2023

Arbutus Announces 2023 Corporate Objectives and Provides Financial Update

January 4, 2023

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

December 12, 2022

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 8, 2022

Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®

October 31, 2022

Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022

October 30, 2022

Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update

October 25, 2022

Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End

September 29, 2022

Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 21, 2022

Arbutus to Participate in September Investor Conferences

September 5, 2022

Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729

August 29, 2022

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 3, 2022

Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

July 20, 2022

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor

July 19, 2022

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update

June 24, 2022

Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022

June 6, 2022

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

June 5, 2022

Arbutus to Participate in June Investor Conferences

June 1, 2022

Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2022

Arbutus to Present at H.C. Wainwright Global Investment Conference

May 16, 2022

Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 4, 2022

Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update

April 20, 2022

Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

March 2, 2022

Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna

February 27, 2022

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

February 27, 2022

Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update

February 16, 2022

Arbutus Announces 2022 Corporate Objectives and Provides Financial Update

January 23, 2022

Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

January 3, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 54 decks. Every deck is listed under its year.